Brief: Lee's Pharmaceutical Says Socazolimab Obtained Phase III Clinical Trial Approval From NMPA
05/03/2021 15:15
March 5 (Reuters) - Lee's Pharmaceutical Holdings Ltd
0950.HK :
* SOCAZOLIMAB OBTAINED APPROVAL FOR A PHASE III CLINICAL
TRIAL
FROM NMPA
Source text https://www1.hkexnews.hk/listedco/listconews/sehk/2021/0305/2021030501425.pdf
Further company coverage: 0950.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lee's Pharmaceutical Holdings
See all newsHong Kong's Lee's Pharmaceutical H1 profit jumps on higher-margin product sales
Brief: Lee's Pharmaceutical Expects H1 Net Profit Of HK$85 Million-HK$95 Million
Brief: Lee's Pharmaceutical Says Investigational New Drug Application For ADC Project ZK2401 Accepted By NMPA
Brief: Ashlins Pharmaceuticals And Lee's Pharm Announce Exclusive License And Supply Agreement Valued At Up To $31 Million
Brief: Lee's Pharmaceutical Says Entered Licensing Agreement With Ashlins Ocular Pharmaceuticals